Patents Examined by Gollamudi S. Kishore
  • Patent number: 10864161
    Abstract: Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 15, 2020
    Assignee: American University of Sharjah
    Inventors: Ghaleb Husseini, Mohammad Al-Sayah, Amal Elsadig
  • Patent number: 10850246
    Abstract: The invention provides a new method for preparing ultra-small polymeric-lipidic delivery nanoparticles (USDNs) that were synthesized by a nanoprecipitation method followed by a layer-by-layer nanodeposition. The USDNs particle size can be controlled between 5-25 nm and provides loading capacities of 22.12% to 72.08%. Moreover, the USDNs platform provides pH controlled drug release, within a terminal release ratio of 68% at pH 5.0 and almost no release to pH of 7.5. Furthermore, based on their small sizes (5-25 nm) and unique composition, the USDNs penetrates the skin strata efficiently, release the payload at the target site as topical or transdermal treatment of a variety of skin disorders. Additionally the USDNs system can be used to treat and diagnoses other crucial diseases (Cancer, Alzheimer, etc) can be combined with various micro-needles or needles free array technologies for special application.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 1, 2020
    Assignee: IndagoMed, LLC
    Inventor: Anamaria Orza
  • Patent number: 10842745
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: November 24, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 10835492
    Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 17, 2020
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
  • Patent number: 10765633
    Abstract: A formulation comprising liposomes, wherein the liposomes comprise, based on the liposome, 0.7 to 3.0 mol % of eritoran or a pharmaceutically acceptable salt thereof and 0.5 to 3.0 mol % of a PEGylated phospholipid.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: September 8, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD
    Inventors: Hiroshi Ishihara, Katsura Hata, Hiroki Muto, Geoff Hird
  • Patent number: 10751283
    Abstract: A shelf stable liposomal based oral rehydration formulation as a mixture has an improved beverage rehydration index performance. The liposomal rehydration salt formulation prevents severe dehydration, maintains body electrolytes and fluids in a human, and rehydrates a human. The formulation includes less than 0.4% phospholipids, having an average size less than 270 nm and an osmolality of about 200 mOsm/kg.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 25, 2020
    Assignee: CAPABILITY BUILDING, INC.
    Inventors: Alcides Nicastro, Gustavo M. Souss
  • Patent number: 10744089
    Abstract: The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: August 18, 2020
    Assignee: UNIVERSITAET BERN
    Inventors: Eduard Babiychuk, Annette Draeger
  • Patent number: 10729651
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: August 4, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
  • Patent number: 10722467
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 28, 2020
    Assignee: ZONEONE PHARMA, INC.
    Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
  • Patent number: 10722464
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 28, 2020
    Assignee: Celator Pharmaceuticals, Inc.
    Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
  • Patent number: 10716757
    Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: July 21, 2020
    Assignee: Universit├Ąt Heidelberg
    Inventors: Gert Fricker, Walter Mier, Frieder Helm, Philipp Uhl, Stephan Urban
  • Patent number: 10709665
    Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: July 14, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Stephanie Kurz, Soroush Ardekani, Kathleen Dunne Albright Los, Katherine Stone, Ernest G. Schutt, Vladimir Kharitonov
  • Patent number: 10702474
    Abstract: The disclosure describes a fusogenic liposome-coated porous silicon nanoparticles for high loading efficiency of anionic payloads (small molecules, dyes, nucleic acids), and for non-endocytic delivery of hydrophilic and lipophilic payloads by membrane fusion. The liposome coating can be further modified with targeting peptides or antibodies via covalent binding chemistry between the ligands and functionalized poly(ethylene glycol). The surface moieties can be transferred to the cellular membrane surface by fusogenic uptake. The composition of the disclosure can be applied in the treatment of diseases by delivering entrapped/encapsulated payloads.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael J. Sailor, Byungji Kim, Jinyoung Kang
  • Patent number: 10702473
    Abstract: A liposome formulation for delivery of Wnt signal pathway inhibitor is provided herein, which comprises lipid molecules and Wnt signal pathway inhibitor, wherein the liposome formulation is prepared through following steps: (1) providing an aqueous solution of the Wnt signal pathway inhibitor and providing an alcoholic solution of the lipid molecules, (2) mixing the aqueous solution of the Wnt signal pathway inhibitor and the alcoholic solution of the lipid molecules, (3) removing alcohol solvent to obtain the liposome formulation with Wnt signal pathway inhibitor encapsulated therein.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: July 7, 2020
    Assignee: Curegenix, Inc.
    Inventors: Yuhong Xu, Meiqing Tu, Xiaojing Chen
  • Patent number: 10675245
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 9, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
  • Patent number: 10660853
    Abstract: Disclosed are a method of preparing liposomes using a mixed solvent of ethyl acetate and n-hexane for dissolving phospholipids, and a method of preparing a liposome frozen powder by putting a container including liposomes in a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, which methods are useful in food industry for no use of toxic chloroform. Disclosed also is adding the produced container including liposomes to a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, thus advantageously preventing deterioration in stability of liposome particles, as well as being almost completely returned to the original state.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: May 26, 2020
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Pahn Shick Chang, Kyung Min Park, Eun Hye Yang, Ho Sup Jung
  • Patent number: 10653796
    Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: May 19, 2020
    Assignee: Universit├Ąt Heidelberg
    Inventors: Philipp Uhl, Max Sauter, Uwe Haberkorn, Walter Mier, Gert Fricker
  • Patent number: 10617672
    Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 14, 2020
    Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.
    Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
  • Patent number: 10617642
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 14, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
  • Patent number: 10610486
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: April 7, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou